Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first approved by the U.S. FDA in November 2013 for the treatment of mantle cell lymphoma (MCL). It has b···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：45
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's m···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：41
Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton's tyrosine kinase. It is used to treat chronic lymphocytic leukemia, mantle cell lymphoma,···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：46
Ibrutinib (Imbruvica) is a type of medication called a kinase inhibitor, used to treat several types of blood cancers, as well as a serious complication of allogeneic stem cell tra···【more】
Article source：Captain MedicineRelease date：2026-03-12Recommended：39
What are the common adverse reactions to Gilteritinib fumarate?Common reactions include: abnormal liver function (elevated ALT/AST), anemia, decreased platelets, febrile neutropeni···【more】
Article source：Captain MedicineRelease date：2026-03-11Recommended：54
What drugs does Gilteritinib Fumarate Tablets interact with?Before taking this medication, you must inform your doctor of all medications you are currently using and any health pro···【more】
Article source：Captain MedicineRelease date：2026-03-11Recommended：47
Use of Gilteritinib Fumarate Tablets with Other MedicationsDuring treatment, doctors may combine Gilteritinib Fumarate Tablets with other leukemia treatments (such as chemotherapy ···【more】
Article source：Captain MedicineRelease date：2026-03-11Recommended：44
Indications and EfficacyThe main component of Gilteritinib Fumarate Tablets is gilteritinib fumarate, which is an anti-tumor medication.This medication should be used under the gui···【more】
Article source：Captain MedicineRelease date：2026-03-11Recommended：41
During treatment with Selumetinib, in addition to its expected therapeutic effects, this medication may cause some adverse effects. While not all side effects occur, some may requi···【more】
Article source：Captain MedicineRelease date：2026-03-10Recommended：68
August 1, 2017 -- The U.S. Food and Drug Administration today approved Enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who h···【more】
Article source：Captain MedicineRelease date：2026-03-10Recommended：47
During treatment with Enasidenib, in addition to the expected therapeutic effects, some adverse effects may also occur. While not all side effects happen, some may require medical ···【more】
Article source：Captain MedicineRelease date：2026-03-10Recommended：53
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect associated with the leukemia drug···【more】
Article source：Captain MedicineRelease date：2026-03-10Recommended：48
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2262025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2322025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
